Last updated on November 2019

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor


Brief description of study

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and in participants with adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), and small cell lung cancer (SCLC) in the expansion part 2, 3, 4, and 5.

Clinical Study Identifier: NCT03207672

Find a site near you

Start Over